Prevencio and Seattle Youngsters’s Analysis Institute Current Extremely Correct Knowledge for First Time Synthetic Intelligence-driven A number of Protein Blood Take a look at for Kawasaki Illness | Enterprise

KIRKLAND, Wash .– (BUSINESS WIRE) – May 4, 2021–

Prevencio, Inc. today announced the presentation of high-accuracy data on an Artificial Intelligence (AI) -driven blood test for Kawasaki Disease (KD) at the Pediatric Academic Societies (PAS) International Meetings. The new test HART KD was developed in cooperation with the Seattle Children’s Research Institute and used the AI-controlled HART platform and Prevencio’s know-how in the development of heart blood tests.

For the first time, KD can be accurately diagnosed with easily measurable, multiple proteins in the blood of children. A key differentiator is the use of an AI-driven algorithm or weighting of each protein to improve accuracy to an impressive 92% (AUC) compared to non-specific single protein tests. This provides a long-needed diagnostic blood test to differentiate KD from other infectious and inflammatory diseases.

“Kawasaki disease is the most common acquired heart disease in children and occurs primarily in children under 5 years of age. The main symptoms are persistent fever and a rash. This makes diagnosis difficult as thousands of children with these symptoms are present in US emergency rooms each year, ”said Dr. Michael Portman, director of pediatric cardiovascular research at Seattle Children’s and professor of pediatrics at the University of Washington School of Medicine. “With COVID-19 Associated Multisystem Inflammatory Syndrome in Children (MIS-C) and Kawasaki disease having similar symptoms, timely and accurate diagnosis of Kawasaki disease is even more critical.”

Without early treatment, there is a 25 to 30% risk of cardiac artery dilation and aneurysm, which can ultimately lead to heart attacks, heart failure, sudden death, and the need for lifelong therapy.

Portman added, “There is currently no specific diagnostic test for Kawasaki disease. We are pleased with the robust 92% accuracy of HART KD and appreciate our collaboration with Prevencio to address this critical, unmet medical need. “

The incidence rates of KD in the United States are 19-25 cases per 100,000 children under five and are increasing. Predictive models estimate that one in every 1,600 American adults will be affected by the disease by 2030. The prevalence rates among children in Asia are even higher. Japan has the highest incidence rate with more than 16,000 new cases per year. Every 60th boy and every 75th girl in Japan develops KD in childhood.

Rhonda Rhyne, Prevencio’s Chief Executive Officer, added, “We are excited to be working with the Seattle Children’s Research Institute, one of the top five pediatric research centers in the country, and are excited to extend the use of our AI Hart platform to the Kawasaki Disease spread. It is worthwhile to help diagnose this life-threatening childhood disease. “

Prevencio is in commercialization talks with protein measurement platform companies for partnerships and licenses to offer HART KD to children suspected of having Kawasaki disease.

About Prevencio HART tests:

Prevencio is based on AI and is revolutionizing blood tests for cardiovascular diseases and customer-specific diagnostics. Using this novel approach, the company has developed seven blood tests that greatly improve the diagnosis of a wide variety of heart and blood vessel-related complications.

Our three lead tests include:

1. HART CADhs ™ – Diagnosing Obstructive Coronary Artery Disease
2. HART CVE ™ – 1 year risk of heart attack, stroke, or cardiac death
3. HART KD ™ – Kawasaki Disease Diagnosis

The results of the HART tests were peer-reviewed 21 times, including at leading cardiovascular meetings (European Society of Cardiology Congress – 2016, 2018; American College of Cardiology Scientific Sessions – 2017, 2018, 2019, 2020; Scientific Sessions of the American Heart Association – 2017, 2018, 2019; American Diabetes Association Scientific Sessions – 2018, 2019; Pediatric Academic Societies International Sessions – 2021) and published in high profile journals – (Journal of American College of Cardiology – March 2017; American Journal of Cardiology – July 2017; Clinical Cardiology – June 2018; Open Heart – November 2018, May 2019; January 2019; Biomarkers in Medicine – June 2020; Journal of American Heart Association – August 2020).

About Prevencio, Inc .:

Prevencio’s value proposition is “Preventing the Avoidable” – that is, avoiding unnecessary procedures, associated side effects and costs, and improving patient outcomes and clinical trials through more accurate blood tests for cardiovascular disease. Prevencio uses machine learning (artificial intelligence) + multi-proteomic biomarker + proprietary algorithms to provide cardiovascular diagnostic and prognostic tests that are much more accurate than standard stress tests. The company is headquartered in Kirkland, Washington. More information is available at www.PrevencioMed.com.

Forward-Looking (Safe Harbor) Declaration:

Except for the historical and factual information contained herein, this press release contains forward-looking statements such as market needs, acceptances, and sizes, the accuracy of which is necessarily subject to uncertainties and risks, including the company’s sole reliance on HART technology and various uncertainties of companies in the development stage. The company makes no commitment to update the information contained in this press release.

View source version on businesswire.com: http://www.businesswire.com/news/home/20210504005611/de/

Christiaan Boer, cboer @ cplusc.com; 406-360-5239

KEYWORD: WASHINGTON UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: TECHNOLOGY HEALTH CONSUMERS OTHER TECHNOLOGY RESEARCH ADOLESCENT INFECTIOUS DISEASES CHILDREN GENERAL HEALTH BABY / MATERNITY SCIENCE DATA MANAGEMENT CLINICAL STUDIES CARDIOLOGY

SOURCE: Prevencio, Inc.

Copyright Business Wire 2021.

PUB: 05/04/2021 09:00 AM / DISC: 05/04/2021 09:02 AM

http://www.businesswire.com/news/home/20210504005611/de

Copyright Business Wire 2021.